These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 36906912)
21. Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy. Talos DM; Jacobs LM; Gourmaud S; Coto CA; Sun H; Lim KC; Lucas TH; Davis KA; Martinez-Lage M; Jensen FE Ann Neurol; 2018 Feb; 83(2):311-327. PubMed ID: 29331082 [TBL] [Abstract][Full Text] [Related]
22. Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment. Heinzen D; Divé I; Lorenz NI; Luger AL; Steinbach JP; Ronellenfitsch MW Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510109 [TBL] [Abstract][Full Text] [Related]
23. mTORC2 regulates renal tubule sodium uptake by promoting ENaC activity. Gleason CE; Frindt G; Cheng CJ; Ng M; Kidwai A; Rashmi P; Lang F; Baum M; Palmer LG; Pearce D J Clin Invest; 2015 Jan; 125(1):117-28. PubMed ID: 25415435 [TBL] [Abstract][Full Text] [Related]
24. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation. Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732 [TBL] [Abstract][Full Text] [Related]
25. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy. Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075 [TBL] [Abstract][Full Text] [Related]
26. TGFβ-induced deptor suppression recruits mTORC1 and not mTORC2 to enhance collagen I (α2) gene expression. Das F; Bera A; Ghosh-Choudhury N; Abboud HE; Kasinath BS; Choudhury GG PLoS One; 2014; 9(10):e109608. PubMed ID: 25333702 [TBL] [Abstract][Full Text] [Related]
27. mTOR substrate phosphorylation in growth control. Battaglioni S; Benjamin D; Wälchli M; Maier T; Hall MN Cell; 2022 May; 185(11):1814-1836. PubMed ID: 35580586 [TBL] [Abstract][Full Text] [Related]
28. The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factor via SGK1 kinase. Mori S; Nada S; Kimura H; Tajima S; Takahashi Y; Kitamura A; Oneyama C; Okada M PLoS One; 2014; 9(2):e88891. PubMed ID: 24558442 [TBL] [Abstract][Full Text] [Related]
29. Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction. Kakiuchi Y; Yurube T; Kakutani K; Takada T; Ito M; Takeoka Y; Kanda Y; Miyazaki S; Kuroda R; Nishida K Osteoarthritis Cartilage; 2019 Jun; 27(6):965-976. PubMed ID: 30716534 [TBL] [Abstract][Full Text] [Related]
30. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition. Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229 [TBL] [Abstract][Full Text] [Related]
31. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells. Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655 [TBL] [Abstract][Full Text] [Related]
32. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis. Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809 [TBL] [Abstract][Full Text] [Related]
33. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058 [TBL] [Abstract][Full Text] [Related]
34. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin. Zou Z; Chen J; Yang J; Bai X Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881 [TBL] [Abstract][Full Text] [Related]
36. Control of B lymphocyte development and functions by the mTOR signaling pathways. Iwata TN; Ramírez-Komo JA; Park H; Iritani BM Cytokine Growth Factor Rev; 2017 Jun; 35():47-62. PubMed ID: 28583723 [TBL] [Abstract][Full Text] [Related]
37. Targeting mTOR Signaling in Type 2 Diabetes Mellitus and Diabetes Complications. Yang L; Zhang Z; Wang D; Jiang Y; Liu Y Curr Drug Targets; 2022; 23(7):692-710. PubMed ID: 35021971 [TBL] [Abstract][Full Text] [Related]
38. Tanc2-mediated mTOR inhibition balances mTORC1/2 signaling in the developing mouse brain and human neurons. Kim SG; Lee S; Kim Y; Park J; Woo D; Kim D; Li Y; Shin W; Kang H; Yook C; Lee M; Kim K; Roh JD; Ryu J; Jung H; Um SM; Yang E; Kim H; Han J; Heo WD; Kim E Nat Commun; 2021 May; 12(1):2695. PubMed ID: 33976205 [TBL] [Abstract][Full Text] [Related]
39. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin. Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604 [TBL] [Abstract][Full Text] [Related]